Overview

Statins for Acutely Injured Lungs From Sepsis

Status:
Terminated

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

Objective: assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI). Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.

Phase:

Phase 3

Details

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Rosuvastatin Calcium